caa a22 4500 445299029 CHVBK 20180317142551.0 cr unu---uuuuu 170323e20100501xx s 000 0 eng 10.1007/s11940-010-0070-0 doi (NATIONALLICENCE)springer-10.1007/s11940-010-0070-0 Myasthenia Gravis [Elektronische Daten] [Agnes Jani-Acsadi, Robert Lisak] Opinion statement: Treatment of patients with acquired (autoimmune) myasthenia gravis should rely on evidence-based therapeutic choices, taking into account the individual's needs according to disease severity (mild to severe), extent (ocular or generalized), comorbidities (including other autoimmune diseases, infections, thymoma, and pregnancy), age, iatrogenic factors (the risks and benefits of therapy), patient autonomy and quality of life, financial burden to the patient, and associated health care costs. Therapy is aimed at managing symptoms by improving neuromuscular junction transmission (cholinesterase inhibitors) and/or modifying the underlying immunopathogenetic cause of acquired myasthenia gravis via immunosuppression or immunomodulation. Myasthenic patients with operable thymoma should be referred for surgery and closely followed up for tumor recurrence. A concerted international effort is addressing treatment recommendations for thymectomy in myasthenic patients with no radiologic evidence of thymoma who are positive for circulating acetylcholine receptor antibodies. There is a lack of evidence-based treatment guidelines for both acute and long-term management of ocular myasthenia. Acute management of myasthenic crisis requires intensive monitoring of the patient and institution of an efficient and safe treatment such as plasma exchange. Patient education is essential to a comprehensive long-term treatment plan. Springer Science+Business Media, LLC, 2010 Jani-Acsadi Agnes Department of Neurology, Neuromuscular Division, Wayne State University, School of Medicine, 8A University Health Center, 4201 St. Antoine, 48201, Detroit, MI, USA aut Lisak Robert Department of Neurology, Wayne State University, School of Medicine, 8A University Health Center, 4201 St. Antoine, 48201, Detroit, MI, USA aut Current Treatment Options in Neurology Current Science Inc. 12/3(2010-05-01), 231-243 1092-8480 12:3<231 2010 12 11940 https://doi.org/10.1007/s11940-010-0070-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11940-010-0070-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jani-Acsadi Agnes Department of Neurology, Neuromuscular Division, Wayne State University, School of Medicine, 8A University Health Center, 4201 St. Antoine, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Lisak Robert Department of Neurology, Wayne State University, School of Medicine, 8A University Health Center, 4201 St. Antoine, 48201, Detroit, MI, USA aut NATIONALLICENCE 773 0- Current Treatment Options in Neurology Current Science Inc 12/3(2010-05-01), 231-243 1092-8480 12:3<231 2010 12 11940 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer